Drug-Induced Bullous Eruption – Decision Support Tool
Drug-Induced Bullous Eruption – Decision Support (HCP)
Triage • Severity • Timing • Causality • Differential • Management • PV/Reg • Print Summary
1) Patient, Exposure & Timing
2) Presentation
Phenotype (suggested)
–
Severity tier
–
Risk window fit
–
Immediate safety: If SJS/TEN suspected → stop suspected drug now; urgent hospital evaluation. Protect skin/mucosa; fluids; pain control; ophthalmology if ocular symptoms.
3) Timing – TTO & Exposure at Onset
Tip: Set Start, Stop (last dose), and Onset dates above to auto-calculate.
Interpretation — second box: + = last dose before onset (stopped X days prior) • 0 = dose on day of onset • − = continued after onset.
Interpretation — second box: + = last dose before onset (stopped X days prior) • 0 = dose on day of onset • − = continued after onset.
Time-to-Onset class
–
Based on drug class & days
Exposure at onset
–
Derived from “last dose → onset”
Urgency hint
–
Admission more likely if severe and on-drug at onset
What counts as a “typical” window?
Many SJS/TEN reactions begin 7–21 days after first exposure (anticonvulsants, sulfonamides, nevirapine, some penicillins/cephalosporins).
Allopurinol: 7–30 days (longer with renal impairment). Oxicam-type NSAIDs: 5–15 days.
Re-exposure/FDE can be much faster (hours).
4) Causality – Quick Score (Naranjo-inspired)
Causality: –
5) Alternatives (look-alikes)
Checklist – exclude competing diagnoses
6) Management (auto-suggest)
7) PV / Regulatory
If serious + unexpected, expedited reporting may apply (often ≤15 calendar days). Include complete timeline, photos, biopsy/DIF, %BSA, mucosal sites, labs, and product details.
8) Case Summary (auto-generated)
Disclaimer: Decision support only; does not replace clinical judgment, dermatology consults, or local protocols.
